BOSTON SCIENTIFIC CORPORATION (NYSE:BSX) Files An 8-K Results of Operations and Financial Condition

BOSTON SCIENTIFIC CORPORATION (NYSE:BSX) Files An 8-K Results of Operations and Financial Condition
ITEM 2.02.RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

Story continues below

On February6, 2019, Boston Scientific Corporation issued a press release announcing financial results for the fourth quarter and full year ended December31, 2018. A copy of the release is furnished with this report as Exhibit 99.1.

The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d)Exhibits

Exhibit No.Description

BOSTON SCIENTIFIC CORP Exhibit
EX-99.1 2 q42018earningsrelease.htm EXHIBIT 99.1 – Q4 2018 EARNINGS RELEASE Exhibit FOR IMMEDIATE RELEASEBOSTON SCIENTIFIC ANNOUNCES RESULTS FORFOURTH QUARTER AND FULL YEAR 2018Marlborough,…
To view the full exhibit click here

About BOSTON SCIENTIFIC CORPORATION (NYSE:BSX)

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and PI businesses. Its Rhythm Management segment consists of CRM and EP businesses. Its MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its interventional cardiology products include Drug-Eluting Coronary Stent Systems, Core Coronary Technology, Intravascular Imaging and Structural Heart Therapy. Its peripheral products include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters.

An ad to help with our costs